Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta, Hopkins MedTech Partner to Offer LDT and IVD Validation Services

NEW YORK – DiaCarta said Monday that it has formed a strategic partnership with New Jersey-based contract research organization Hopkins MedTech Compliance/Hopkins MedTech Lab Services to provide validation and regulatory compliance services for laboratory test and in vitro diagnostic developers in the US.

The companies aim to fill an unmet need, helping companies who have developed novel IVD tests but do not have the capacity to advance their products for FDA approval or to establish them as LDTs.

"Working with DiaCarta, we can now meet the increasing demand from our customers for their LDT development needs while waiting for product approvals by the FDA," Homer Wu, CEO of HMC and HML, said in a statement.

Based in Pleasanton, California, DiaCarta has developed several blood-based molecular diagnostics using proprietary technologies for selectively amplifying target sequences. Its tests include the ColoScape colorectal cancer mutation test and the RadTox assay for personalizing radiation and chemotherapy treatment.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.